10/530647

JC13 2 'd PCT/PTO 0 6 APR 2005

IN THE CATED STATES DESIGNATED OFFICE (DO/US)

In Re the Ap	plication of:	΄/	
HOR	ISAKA et al.		INFORMATION DISCLOSURE STATEMENT
Int'l. Serial N	No.: PCT/JP2003/016671)	<u>UTAT DIVIDI</u>
Int'l. Filing I	Date: December 25, 2003)	"EXPRESS MAIL" MAILING PABEL NUMBER: EV492325942US DATE OF DEPOSIT:
Priority Date	e: December 26, 2002)	I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE
U.S. Serial N	No.:))	UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO COMMISSIONER FOR PATENTS, BOX PCT, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.
INFO MED	ASS SUBSTRATE FOR DRMATION RECORDING DIUM AND METHOD FOR NUFACTURING THE SAME")	SIGNATURE: JANICE MESSER SIGNATURE: MUSEL MESSER SIGNATURE: MUSEL MESSER MESSER
Atty. File No	о.: 2933НС-1)	
P.O. Box 14	er for Patents		
Dear Sir:			
The recognition The recognitio	references cited on attached Fo	rm PT	O-1449 are being called to the attention of the
×	Copies of the cited non-pater	nt and/	or foreign references are enclosed herewith.
	Copies of the cited U.S. pate	nts and	d/or patent applications are enclosed herewith.
×	Copies of the cited U.S. pate	nts/pa	tent application publications are not enclosed in
accordance v	with the waivers dated July 11, 2	003 an	d October 19, 2004, whereby patent applications
, 0	•	ıbmit c	opies of U.S. patents and U.S. patent application
publications.	•		
	Copies of the cited references	are no	t enclosed, in accordance with 37 C.F.R. 1.98(d),
because the i	references were cited by or subn	nitted 1	to the U.S. Patent and Trademark Office in prior
application S	Serial No filed _		, which is relied upon for an earlier
filing date u	nder 35 U.S.C. § 120.		

⊠	To the best or appli	To the best or applicants' belief, the pertinence of the foreign-language references are					
believed to	o be summarized in the	attached English abstracts and in the figures, although applicants					
do not nec	cessarily vouch for the a	ccuracy of the translation.					
	Examiner's attenti	on is drawn to the following co-pending applications, copies of					
which hav	ve been or are being sub	mitted:					
	Serial No.	filed					
	Serial No.	filed					
	Other:						

Submission of the above information is not intended as an admission that any item is citable under the statutes or rules to support a rejection, that any item disclosed represents analogous art, or that those skilled in the art would refer to or recognize the pertinence of any reference without the benefit of hindsight, nor should an inference be drawn as to the pertinence of the references based on the order in which they are presented. Submission of this statement should not be taken as an indication that a search has been conducted, or that no better art exists.

It is respectfully requested that the cited information be expressly considered during the prosecution of this application and the references made of record therein.

FEES

Ø	37 CFR 1.97(b): No fee is believed due in connection with this submission, because the information disclosure statement submitted herewith is satisfies one of the following conditions ("X" indicates satisfaction):					
	Within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d), or					
	Within three months of the date of entry into the national stage of an international application as set forth in 37 CFR 1.491 or					
	. Before the mailing date of a first Office Action on the merits, or					
	Before the mailing of a first Office action after the filing of a request for continued examination under 37 CFR 1.114.					
	Although no fee is believed due, if any fee is deemed due in connection with this submission, please charge such fee to Deposit Account 19-1970.					
	37 CFR 1.97(c): The information disclosure statement transmitted herewith is being filed after all the above conditions (37 CFR 1.97(b)), but before the mailing date of one of the following conditions: (1) a final action under 37 C.F.R. 1.113 or (2) a notice of allowance under 37 C.F.R. 1.311, or (3) an action that otherwise closes prosecution in the application. This Information Disclosure Statement is accompanied by:					
	□ A Certification (below) as specified by 37 C.F.R. 1.97(e). Although no fee is believed due, if any fee is deemed due in connection with this submission, please charge such fee to Deposit Account 19-1970. OR □ Please charge Deposit Account 19-1970 in the amount of \$180.00 for the fee set forth in 37 C.F.R. 1.1 for submission of an information disclosure statement. Please credit any overpayment or charge any underpayment to Deposit Account 19-1970.					

JC13 Rec'd PCT/PTO 06 APR 2005

37 CFR 1.97(d): This information Disclosure Statement is being submitted after the period specified in 37 CFR 1.97(c).
☐ This information Disclosure Statement includes a Certification (below) as specified by 37 C.F.R. 1.97(e) AND
Applicants hereby requests consideration of the reference(s) disclosed herein. Please charge Deposit Account 19-1970 in the amount of \$180.00 under 37 C.F.R. 1.17(p). Please credit any overpayment or charge any underpayment to Deposit Account 19-1970. Election to pay the fee should not be taken as an indication that applicant(s) cannot execute a certification.
Certification (37 C.F.R. 1.97(e)) (Applicable only if checked)
☐ The undersigned certifies that:
Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. 37 C.F.R. 1.97(e)(1).
☐ A copy of the communication from the foreign patent office is enclosed.
OR
No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this statement. 37 C.F.R. 1.97(e)(2).
Respectfully submitted,
SHERIDAN ROSS P.C.
By: Robert D. Traver Registration No. 47,999 1560 Broadway, Suite 1200 Denver, Colorado 80202-5141

-3-

Date: 6 April 2005

(303) 863-9700

10/530647

JC13 Rec CT/PTO 0 6 APR 2005

0 1 10 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1				Comprete if Known		
Substitute for form 1449A/PTO				Application Number		
IN	FORMAT	ION DISC	CLOSURE	Filing Date		
			PLICANT	First Named Inventor	Tamaki Horisaka	
0.	VI PIM PI	11 51 7.	LIOAII	Art Unit		
				Examiner Name		
Sheet	Sheet 1 of 1		Attorney Docket Number	2933HC-1		
Sheet	1	of	1	Attorney Docket Number	2933HC-1	

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.¹	Document Number Number-kind Code ^{2 (d known)}	Publication Date MM-DD-YYYY	Name of Patentee of Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		US-3,284,274	11/08/1966	HULSLANDER et al.			
		US-5,868,953	02/09/1999	MAEKAWA et al.			
		US-					
		US-					
		US-					
		US- ,					
		US-					
		US-					
		US-					
		US-					

	, 	•		TOKE	GN PATENT DO	JOURENTO	· ·	
Examiner Initials*	Cite No.1	Country		eign Patent Document ; Number¹; Kind Code³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
		JP	-	11-154325	06/08/1999	Hoya Corp.		
		JP	-	2000-218535	. 08/08/2000	Daido Steel Co., Ltd		
		JP	Ţ-	09-174428	07/08/1997	Toshiba Corp.		
		JP	-	08-255774	10/01/1996	Sony Corp.		
			-			·		
			-					
		1	-				*	1

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)						
Examiner Initials*	Cite No.1					

Examiner		Date	
Sigature		Considered	

^{*}EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.